Gordon, K., Papp, K., Gooderman, M., Thaci, D., Foley, P., Morita, A., Kundu, S., Kisa, R., Napoli, A. and Banerjee, S. 2019. Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S14. DOI:https://doi.org/10.25251/skin.3.supp.14.